Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H20N2O2.C4H8O2 |
Molecular Weight | 324.4152 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC(O)=O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1
InChI
InChIKey=JJCJKGKSHRXGHT-UHFFFAOYSA-N
InChI=1S/C13H20N2O2.C4H8O2/c1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11;1-2-3-4(5)6/h5-8H,3-4,9-10,14H2,1-2H3;2-3H2,1H3,(H,5,6)
Procaine is an anesthetic agent indicated for production of local or regional anesthesia, particularly for oral surgery. Procaine (like cocaine) has the advantage of constricting blood vessels which reduces bleeding, unlike other local anesthetics like lidocaine. Procaine is an ester anesthetic. It is metabolized in the plasma by the enzyme pseudocholinesterase through hydrolysis into para-aminobenzoic acid (PABA), which is then excreted by the kidneys into the urine. Procaine acts mainly by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is thus inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel. Procaine has also been shown to bind or antagonize the function of N-methyl-D-aspartate (NMDA) receptors as well as nicotinic acetylcholine receptors and the serotonin receptor-ion channel complex.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6082561 | http://www.abcam.com/procaine-hydrochloride-ab120865.html
Curator's Comment: Crosses the blood-brain barrier.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
60.0 nM [IC50] | |||
Target ID: CHEMBL2362997 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8531111 |
50.0 µM [IC50] | ||
Target ID: CHEMBL4787 |
|||
Target ID: CHEMBL2411 |
1.7 µM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Procaine Approved UseProcaine is a local anesthetic. Procaine causes loss of feeling (numbness) of skin and mucous membranes.
Procaine is used as an injection during surgery and other medical and dental procedures. Launch Date1972 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/573562/ |
60 mg/kg single, intravenous dose: 60 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PROCAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.5 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/573562/ |
60 mg/kg single, intravenous dose: 60 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PROCAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.3 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/573562/ |
60 mg/kg single, intravenous dose: 60 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PROCAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
50 mg 1 times / day multiple, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: Page: p.304 |
healthy, 72.8 n = 119 Health Status: healthy Condition: Age-related decline Age Group: 72.8 Sex: M+F Population Size: 119 Sources: Page: p.304 |
Disc. AE: Systemic lupus erythematosus synd... AEs leading to discontinuation/dose reduction: Systemic lupus erythematosus synd (0.84%) Sources: Page: p.304 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Systemic lupus erythematosus synd | 0.84% Disc. AE |
50 mg 1 times / day multiple, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: Page: p.304 |
healthy, 72.8 n = 119 Health Status: healthy Condition: Age-related decline Age Group: 72.8 Sex: M+F Population Size: 119 Sources: Page: p.304 |
PubMed
Title | Date | PubMed |
---|---|---|
The incidence of systemic side-effects following subconjunctival Mydricaine no. 1 injection. | 1999 Dec |
|
Effects of anticonvulsants on local anaesthetic-induced neurotoxicity in rats. | 2000 Feb |
|
Changes in seizure susceptibility to local anesthetics by repeated administration of cocaine and nomifensine but not GBR12935: possible involvement of noradrenergic system. | 2000 Jul |
|
Swelling of capillary endothelial cells and cardiomyocytes in the ischaemic myocardium of artificially arrested canine hearts. | 2001 |
|
Local anaesthetic effectivity and toxicity of fomocaine, five N-free fomocaine metabolites and two chiralic fomocaine derivatives in rats compared with procaine. | 2001 |
|
[Potentiation of local anesthesia in endonasal surgery]. | 2001 |
|
Calcification in the planula and polyp of the hydroid Hydractinia symbiolongicarpus (Cnidaria, Hydrozoa). | 2001 Aug |
|
The insular but not the perirhinal cortex is involved in the expression of fully-kindled amygdaloid seizures in rats. | 2001 Aug |
|
Local anesthetics noncompetitively inhibit function of four distinct nicotinic acetylcholine receptor subtypes. | 2001 Dec |
|
The effects of intracellular pH changes on resting cytosolic calcium in voltage-clamped snail neurones. | 2001 Feb 1 |
|
The mechanism of maitotoxin-induced elevation of the cytosolic free calcium level in rat cerebrocortical synaptosomes. | 2001 Jan |
|
Penicillin concentrations in serum, milk, and urine following intramuscular and subcutaneous administration of increasing doses of procaine penicillin G in lactating dairy cows. | 2001 Jul |
|
Common solvent toxicity: autoxidation of respiratory redox-cyclers enforced by membrane derangement. | 2001 Jul-Aug |
|
[Hoigne syndrome as an acute non-allergic reaction to different drugs: case reports]. | 2001 Jun |
|
Retention behaviour and fluorimetric detection of procaine hydrochloride using carboxymethyl-beta-cyclodextrin as an additive in reversed-phase liquid chromatography. | 2001 Jun 15 |
|
High epidural block with chloroprocaine in a parturient with low pseudocholinesterase activity. | 2001 Mar |
|
Periorbital allergic contact dermatitis from oxybuprocaine. | 2001 Mar |
|
Spinal anesthesia: a comparison of procaine and lidocaine. | 2001 May |
|
Comparison of volatile anesthetic actions on intracellular calcium stores of vascular smooth muscle: investigation in isolated systemic resistance arteries. | 2001 May |
|
Bronchoconstrictive and relaxant effects of lidocaine on the airway in dogs. | 2001 May |
|
Changes in the flow properties of phospholipid dispersions induced by procaine hydrochloride. Effect of pH and temperature. | 2001 May-Jul |
|
Local anaesthetic activity of beta-caryophyllene. | 2001 May-Jul |
|
Neurotoxicity of spinal procaine--a caution. | 2001 May-Jun |
|
[Investigation on the mechanisms of leukocyte alteration in patients with intolerance to some drugs (with novocaine as a model)]. | 2001 Nov-Dec |
|
[Interactions of histamine and glucocorticoids with nerve structures of respiration passages]. | 2001 Oct |
|
[Infusion therapy with procaine in acute tinnitus]. | 2001 Oct |
|
Optimisation and validation of a capillary electrophoresis method for the simultaneous determination of diazepam and otilonium bromide. | 2001 Oct |
|
[Treatment of animals with acute and/or chronic complaints by electric stimulation therapy]. | 2001 Oct 15 |
|
Role of the dopamine transporter and the sodium channel in the cocaine-like discriminative stimulus effects of local anesthetics in rats. | 2001 Sep |
|
Cembranoid and long-chain alkanol sites on the nicotinic acetylcholine receptor and their allosteric interaction. | 2001 Sep 18 |
|
Oxybuprocaine induces a false-positive response in immunochromatographic SAS Adeno Test. | 2002 Apr |
|
Intrapericardial procaine affects volume expansion-induced fos immunoreactivity in unanesthetized rats. | 2002 Apr |
|
Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. | 2002 Feb |
|
Ionic basis of the resting membrane potential and action potential in the pharyngeal muscle of Caenorhabditis elegans. | 2002 Feb |
|
Chloroprocaine is less painful than lidocaine for skin infiltration anesthesia. | 2002 Feb |
|
The inhibition of the N-methyl-D-aspartate receptor channel by local anesthetics in mouse CA1 pyramidal neurons. | 2002 Feb |
|
Improved right heart function after myocardial preservation with 2,3-butanedione 2-monoxime in a porcine model of allogenic heart transplantation. | 2002 Jan |
|
Short-acting peribulbar anesthesia with 2-chloroprocaine. | 2002 Jan |
|
Allergy to local anaesthetics in dentistry. Myth or reality? | 2002 Jan-Feb |
|
Liver preservation with HTK: salutary effect of hypothermic aerobiosis by either gaseous oxygen or machine perfusion. | 2002 Jun |
|
Non-surgical management of rectal tears in two mares. | 2002 Mar |
|
Biochemical and morphological changes in pancreas stored under hypothermic conditions. | 2002 Mar |
Sample Use Guides
Adults
Local or Regional Anesthesia
Local Infiltration
Usually, 350–600 mg, administered as diluted solution (i.e., 140–240 mL of a 0.25% solution or 70–120 mL of a 0.5% solution)
Peripheral Nerve Block
Up to 1 g, administered undiluted (i.e., 100 mL of a 1% injection) or as diluted solution (i.e., 200 mL of a 0.5% solution).
For local infiltration or peripheral nerve block, inject slowly and avoid rapid injection of large volumes; when feasible, administer in fractional (incremental) doses. For subarachnoid (spinal) block, use 2-mL single-dose ampuls containing procaine hydrochloride 10% only.c d Position patient properly prior to spinal anesthesia.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11812692
Procaine 0.2 mM reduced the maximal NMDA-induced currents without affecting the 50% effective concentration values for NMDA in mouse CA1 pyramidal neurons..
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
136-55-0
Created by
admin on Fri Dec 15 17:24:55 GMT 2023 , Edited by admin on Fri Dec 15 17:24:55 GMT 2023
|
PRIMARY | |||
|
m9145
Created by
admin on Fri Dec 15 17:24:55 GMT 2023 , Edited by admin on Fri Dec 15 17:24:55 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID40159622
Created by
admin on Fri Dec 15 17:24:55 GMT 2023 , Edited by admin on Fri Dec 15 17:24:55 GMT 2023
|
PRIMARY | |||
|
20056864
Created by
admin on Fri Dec 15 17:24:55 GMT 2023 , Edited by admin on Fri Dec 15 17:24:55 GMT 2023
|
PRIMARY | |||
|
J91Z1P9X9X
Created by
admin on Fri Dec 15 17:24:55 GMT 2023 , Edited by admin on Fri Dec 15 17:24:55 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD